NFE2L2 and rheumatoid arthritis: Future work should include animal experimentation and clinical studies to assess whether pharmacological inhibition of 11β-HSD1 or GR antagonism may improve Nrf2-dependent cell defense and whether such intervention may be beneficial for ALD patients or for patients with chronic inflammation such as diabetes or rheumatoid arthritis.